By vgreene, 28 October, 2021 28 day all cause mortality higher w HCQ vs SOC only RR 1 09 95 CI 0 97 to 1 23 similarly across subgroups HCQ group less likely to be discharged alive w in 28 days vs SOC rate ratio 0 9 95 CI 0 83 0 98 among pts not mech vent baseline HCQ group w higher f
By vgreene, 28 October, 2021 Hospitalized pts mean age 65 4y w suspected or confirmed COVID 19 randomized to HCQ 800 mg q6h x2 then 400 mg q12h plus SOC for up to 10 days n 1 561 vs SOC only n 3 155 at randomization 17 invasive mech vent 60 O2 only
By vgreene, 28 October, 2021 Randomized controlled open label adaptive platform study current analysis incl HCQ vs SOC only results for other tx arms published or forthcoming
By vgreene, 28 October, 2021 Study considerations randomized but open label HCQ dose based on PK modeling limited number of intubated pts no children enrolled no collection of virological or laboratory parameters
By vgreene, 28 October, 2021 28 day all cause mortality higher w HCQ vs SOC only RR 1 09 95 CI 0 97 to 1 23 similarly across subgroups HCQ group less likely to be discharged alive w in 28 days vs SOC rate ratio 0 9 95 CI 0 83 0 98 among pts not mech vent baseline HCQ group w higher f
By vgreene, 28 October, 2021 Hospitalized pts mean age 65 4y w suspected or confirmed COVID 19 randomized to HCQ 800 mg q6h x2 then 400 mg q12h plus SOC for up to 10 days n 1 561 vs SOC only n 3 155 at randomization 17 invasive mech vent 60 O2 only
By vgreene, 28 October, 2021 Randomized controlled open label adaptive platform study current analysis incl HCQ vs SOC only results for other tx arms published or forthcoming
By vgreene, 28 October, 2021 Study considerations randomized but open label HCQ dose based on PK modeling limited number of intubated pts no children enrolled no collection of virological or laboratory parameters
